Loading...

Resverlogix

DB:RFS
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RFS
DB
CA$801M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Resverlogix Corp., a development stage company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibitior in the United States and Canada. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
  • Resverlogix has significant price volatility in the past 3 months.
RFS Share Price and Events
7 Day Returns
44.4%
DB:RFS
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
240.7%
DB:RFS
-10.6%
DE Biotechs
-6.2%
DE Market
RFS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Resverlogix (RFS) 44.4% 34% 42.2% 240.7% 239.2% 612.9%
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • RFS outperformed the Biotechs industry which returned -10.6% over the past year.
  • RFS outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
RFS
Industry
5yr Volatility vs Market

Value

 Is Resverlogix undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Resverlogix is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Resverlogix has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Resverlogix. This is due to cash flow or dividend data being unavailable. The share price is €3.0155.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Resverlogix's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Resverlogix's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:RFS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in USD $-0.60
TSX:RVX Share Price ** TSX (2019-04-23) in CAD CA$4.15
TSX:RVX Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.745 $3.09
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Resverlogix.

DB:RFS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:RVX Share Price ÷ EPS (both in USD)

= 3.09 ÷ -0.60

-5.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Resverlogix is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Resverlogix is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Resverlogix's expected growth come at a high price?
Raw Data
DB:RFS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
41.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Resverlogix, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Resverlogix's assets?
Raw Data
DB:RFS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in USD $-0.80
TSX:RVX Share Price * TSX (2019-04-23) in CAD CA$4.15
TSX:RVX Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.745 $3.09
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:RFS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:RVX Share Price ÷ Book Value per Share (both in USD)

= 3.09 ÷ -0.80

-3.86x

* Primary Listing of Resverlogix.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Resverlogix has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at our analysis of RFS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Resverlogix's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Resverlogix's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Resverlogix has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Resverlogix expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
41.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Resverlogix expected to grow at an attractive rate?
  • Unable to compare Resverlogix's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Resverlogix's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Resverlogix's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:RFS Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:RFS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 41.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:RFS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:RFS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-04-30 408 1
2022-04-30 197 1
2021-04-30 45 -46 2
2020-04-30 0 -56 2
2019-04-30 0 -110 2
DB:RFS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-01-31 -43 -110
2018-10-31 -44 -121
2018-07-31 -38 -92
2018-04-30 -25 -58
2018-01-31 -25 -62
2017-10-31 -23 -51
2017-07-31 -28 -55
2017-04-30 -23 -46
2017-01-31 -23 -44
2016-10-31 -26 -40
2016-07-31 -20 -29
2016-04-30 -21 -20

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Resverlogix is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Resverlogix is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:RFS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Resverlogix Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RFS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-04-30
2022-04-30
2021-04-30 -0.22 -0.22 -0.22 1.00
2020-04-30 -0.27 -0.23 -0.31 2.00
2019-04-30 -0.59 -0.59 -0.59 1.00
DB:RFS Past Financials Data
Date (Data in USD Millions) EPS *
2019-01-31 -0.60
2018-10-31 -0.70
2018-07-31 -0.60
2018-04-30 -0.42
2018-01-31 -0.51
2017-10-31 -0.47
2017-07-31 -0.52
2017-04-30 -0.44
2017-01-31 -0.42
2016-10-31 -0.38
2016-07-31 -0.27
2016-04-30 -0.20

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Resverlogix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Resverlogix's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Resverlogix has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Resverlogix performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Resverlogix's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Resverlogix does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Resverlogix's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Resverlogix's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Resverlogix's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Resverlogix Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RFS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 -110.31 5.68 32.72
2018-10-31 -120.77 5.05 36.88
2018-07-31 -92.45 4.19 36.12
2018-04-30 -58.31 4.07 37.49
2018-01-31 -61.67 4.05 36.69
2017-10-31 -50.80 4.08 33.43
2017-07-31 -55.09 4.19 31.63
2017-04-30 -46.21 4.27 29.76
2017-01-31 -44.32 4.49 27.19
2016-10-31 -40.20 4.32 22.45
2016-07-31 -28.84 3.97 19.34
2016-04-30 -19.72 4.33 15.37
2016-01-31 -29.99 4.25 11.10
2015-10-31 -22.77 4.40 8.12
2015-07-31 -22.30 4.55 5.64
2015-04-30 -18.32 4.27 4.19
2015-01-31 2.00 4.10 3.82
2014-10-31 18.93 4.04 3.82
2014-07-31 20.35 4.00 4.23
2014-04-30 55.10 4.23 9.31
2014-01-31 42.46 5.45 14.72
2013-10-31 14.36 5.89 20.76
2013-07-31 5.98 6.16 26.60
2013-04-30 -43.36 6.21 28.08
2013-01-31 -37.92 5.42 26.52
2012-10-31 -31.75 5.25 23.83
2012-07-31 -25.82 5.36 22.40
2012-04-30 -18.78 5.27 19.19

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Resverlogix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Resverlogix has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Resverlogix improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Resverlogix's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Resverlogix has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Resverlogix's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Resverlogix's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Resverlogix's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Resverlogix's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Resverlogix's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Resverlogix has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Resverlogix Company Filings, last reported 2 months ago.

DB:RFS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 -156.46 111.18 6.49
2018-10-31 -155.80 108.86 5.94
2018-07-31 -132.89 106.54 5.77
2018-04-30 -83.68 54.71 0.12
2018-01-31 -78.48 49.10 0.52
2017-10-31 -118.84 99.92 0.71
2017-07-31 -111.23 98.98 0.39
2017-04-30 -101.57 91.34 1.36
2017-01-31 -90.48 88.91 4.95
2016-10-31 -77.71 86.06 12.80
2016-07-31 -62.61 83.11 24.16
2016-04-30 -56.43 81.92 28.11
2016-01-31 -47.09 76.58 29.93
2015-10-31 -38.45 73.83 42.41
2015-07-31 -34.90 72.67 48.01
2015-04-30 -73.73 72.54 16.21
2015-01-31 -55.04 70.96 17.01
2014-10-31 -53.41 73.48 23.25
2014-07-31 -54.01 51.17 0.46
2014-04-30 -63.22 60.47 0.59
2014-01-31 -64.42 60.09 0.47
2013-10-31 -80.32 78.75 1.70
2013-07-31 -83.55 78.59 2.90
2013-04-30 -29.50 26.66 17.41
2013-01-31 -20.22 17.44 10.92
2012-10-31 -7.82 17.14 16.09
2012-07-31 -4.59 0.00 1.45
2012-04-30 2.74 0.00 7.56
  • Resverlogix has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Resverlogix's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Resverlogix has less than a year of cash runway based on current free cash flow.
  • Resverlogix has less than a year of cash runway if free cash flow continues to grow at historical rates of 25.4% each year.
X
Financial health checks
We assess Resverlogix's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Resverlogix has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Resverlogix's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Resverlogix dividends.
If you bought €2,000 of Resverlogix shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Resverlogix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Resverlogix's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:RFS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:RFS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-04-30
2022-04-30
2021-04-30
2020-04-30
2019-04-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Resverlogix has not reported any payouts.
  • Unable to verify if Resverlogix's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Resverlogix's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Resverlogix has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Resverlogix's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Resverlogix afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Resverlogix has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Resverlogix's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Don McCaffrey
COMPENSATION $691,505
TENURE AS CEO 16 years
CEO Bio

Mr. Donald J. McCaffrey, also known as Don, is a Co-Founder of Resverlogix Corporation and has been its Chief Executive Officer, President since April 25, 2003 and has also been its Chairman of the Board since April 2016. Mr. McCaffrey also serves as an Advisor for emerging biotechnology companies. Mr. McCaffrey served as Secretary at Resverlogix Corporation. From January 2001 to April 2002, he served as the President of BioCellogix Inc. He served as President of Resverlogix Inc. since 2001. He served as President of the BioFuture Conference. From September 1995 to January 2001, he served as President of Northern Exhibitions. He has been a Director of BioCellogix Inc., since 1999 and Resverlogix Corporation since April 25, 2003. He served as a Director of Stem Cell Therapeutics Corp. from November 1, 2004 to March 2006. Mr. McCaffrey served as an Independent Director of Amorfix Life Sciences Ltd since September 20, 2005.

CEO Compensation
  • Don's compensation has been consistent with company performance over the past year.
  • Don's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Resverlogix management team in years:

11.9
Average Tenure
  • The average tenure for the Resverlogix management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Don McCaffrey

TITLE
Co-Founder
COMPENSATION
$692K
TENURE
16 yrs

Brad Cann

TITLE
Chief Financial Officer
COMPENSATION
$344K
TENURE
9.5 yrs

Ken Lebioda

TITLE
Senior Vice President of Business & Corporate Development
COMPENSATION
$330K
TENURE
14.3 yrs

Jan Johansson

TITLE
Senior Vice President of Medical Affairs
COMPENSATION
$306K
TENURE
15.1 yrs

Mike Sweeney

TITLE
Senior Vice President of Clinical Development
COMPENSATION
$646K
AGE
57
TENURE
4.4 yrs

Norman C. Wong

TITLE
Co-Founder

Paul Moon

TITLE
Vice President of Investor Relations & Communications

Sarah Zapotichny

TITLE
Director of Investor Relations & Corporate Communications

Ewelina Kulikowski

TITLE
Senior Vice President of Research & Development
TENURE
3 yrs
Board of Directors Tenure

Average tenure of the Resverlogix board of directors in years:

6.8
Average Tenure
  • The tenure for the Resverlogix board of directors is about average.
Board of Directors

Norman C. Wong

TITLE
Co-Founder
TENURE
6 yrs

Kelly McNeill

TITLE
Independent Director
COMPENSATION
$24K
TENURE
9.5 yrs

Don McCaffrey

TITLE
Co-Founder
COMPENSATION
$692K
TENURE
3 yrs

Ken Zuerblis

TITLE
Director
COMPENSATION
$26K
AGE
59
TENURE
8.6 yrs

Eldon Smith

TITLE
Lead Director
AGE
78
TENURE
3 yrs

Bengt Winblad

TITLE
Chairman of Neurodegenerative Clinical & Scientific Advisory Board
TENURE
6.8 yrs

Kam Kalantar-Zadeh

TITLE
Chairman of Renal Clinical Advisory Board

Jeff Cummings

TITLE
Member of Neurodegenerative Clinical & Scientific Advisory Board
TENURE
6.8 yrs

Henrik Zetterberg

TITLE
Member of Neurodegenerative Clinical & Scientific Advisory Board
TENURE
6.8 yrs

Rada Koldamova

TITLE
Member of Neurodegenerative Clinical & Scientific Advisory Board
TENURE
6.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
01. Apr 19 Buy Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Company 29. Mar 19 29. Mar 19 4,479,793 €2.00 €8,959,183
31. Jan 19 Buy Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Company 31. Jan 19 31. Jan 19 2,213,398 €1.99 €4,409,555
X
Management checks
We assess Resverlogix's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Resverlogix has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Resverlogix Corp., a development stage company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibitior in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in Phase III clinical trials for the treatment of patients with cardiovascular diseases, diabetes mellitus, chronic kidney diseases, renal diseases, peripheral artery diseases, orphan diseases, and neurodegenerative diseases. The company is headquartered in Calgary, Canada.

Details
Name: Resverlogix Corp.
RFS
Exchange: DB
Founded:
CA$532,742,916
200,303,934
Website: http://www.resverlogix.com
Address: Resverlogix Corp.
4820 Richard Road SW,
Suite 300,
Calgary,
Alberta, T3E 6L1,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX RVX Common Shares The Toronto Stock Exchange CA CAD 25. Apr 2003
OTCPK RVXC.F Common Shares Pink Sheets LLC US USD 25. Apr 2003
DB RFS Common Shares Deutsche Boerse AG DE EUR 25. Apr 2003
LSE 0VF9 Common Shares London Stock Exchange GB CAD 25. Apr 2003
Number of employees
Current staff
Staff numbers
30
Resverlogix employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 21:37
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/02
Last earnings filing: 2019/03/15
Last earnings reported: 2019/01/31
Last annual earnings reported: 2018/04/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.